Ono Pharmaceutical Co., Ltd. is a pharmaceutical company based in Japan, specializing in drug discovery to address unmet medical needs. With a medium risk ESG score of 21.2, Ono Pharmaceutical focuses on sustainability and governance in its global specialty pharmaceutical business. The company's revenue is segmented into eight categories, with circulatory and respiratory drugs leading the way, followed by metabolic drugs and vitamins. Ono Pharmaceutical also generates revenue from royalties. While most of the company's sales come from Japan, it also has a presence in Asia and Europe. ESG principles are at the core of Ono Pharmaceutical's operations, ensuring a focus on environmental responsibility, sustainability, and governance.